Concepts (67)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 5 | 2024 | 2482 | 0.280 |
Why?
|
| Mastectomy | 2 | 2024 | 63 | 0.210 |
Why?
|
| Mastectomy, Segmental | 2 | 2019 | 27 | 0.190 |
Why?
|
| Carcinoma, Papillary | 1 | 2018 | 77 | 0.150 |
Why?
|
| Radiotherapy | 1 | 2018 | 139 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 225 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 991 | 0.110 |
Why?
|
| Granulomatous Mastitis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Hospitals, County | 1 | 2013 | 23 | 0.110 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 97 | 0.110 |
Why?
|
| Fibroadenoma | 1 | 2012 | 9 | 0.100 |
Why?
|
| Phyllodes Tumor | 1 | 2012 | 11 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2021 | 143 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 1215 | 0.080 |
Why?
|
| Breast | 2 | 2024 | 214 | 0.080 |
Why?
|
| Indocyanine Green | 1 | 2008 | 58 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 260 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2019 | 1166 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2008 | 374 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2024 | 51 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2024 | 326 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 4490 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 203 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2021 | 15930 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 354 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 25931 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 410 | 0.040 |
Why?
|
| Cholecystitis | 1 | 1997 | 20 | 0.040 |
Why?
|
| Neoplasms | 1 | 2012 | 2750 | 0.040 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1997 | 42 | 0.040 |
Why?
|
| Cholecystectomy | 1 | 1997 | 56 | 0.040 |
Why?
|
| SEER Program | 1 | 2018 | 193 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 1870 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1997 | 138 | 0.030 |
Why?
|
| Female | 7 | 2024 | 65309 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1005 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 602 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1303 | 0.030 |
Why?
|
| Adult | 4 | 2024 | 28980 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1240 | 0.030 |
Why?
|
| Humans | 8 | 2024 | 122997 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6359 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1993 | 0.030 |
Why?
|
| Mammography | 1 | 2013 | 113 | 0.030 |
Why?
|
| Steroids | 1 | 2013 | 203 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3259 | 0.020 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2012 | 29 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 350 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 1239 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 1419 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5031 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 945 | 0.020 |
Why?
|
| Gamma Cameras | 1 | 2008 | 6 | 0.020 |
Why?
|
| Axilla | 1 | 2008 | 38 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2008 | 151 | 0.020 |
Why?
|
| Sternum | 1 | 2008 | 53 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2008 | 53 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 2027 | 0.020 |
Why?
|
| Aged | 2 | 2019 | 19035 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 398 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2105 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 753 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2395 | 0.010 |
Why?
|
| Cholelithiasis | 1 | 1997 | 17 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 230 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 1997 | 12087 | 0.000 |
Why?
|
| Male | 1 | 1997 | 59901 | 0.000 |
Why?
|